These findings mirror earlier success observed in a China-only late-stage study, providing a consistent clinical signal for the drug often referred to as ris-rez. The data strengthen the case for accelerated regulatory pathways as the company looks to expand its oncology footprint.
In section Market Quotes
GSK Lung-Cancer Drug Shows Promise in Global Trial
A global clinical trial for risvutatug rezetecan, a lung-cancer therapy licensed by GSK from China's Hansoh Pharmaceutical Group, has yielded a 61% objective response rate. Patients receiving the treatment experienced measurable tumor shrinkage or complete disappearance, reinforcing the drugmaker's strategy to fast-track its development for advanced malignancies.
GSK is currently managing late-stage trials for ris-rez targeting advanced lung and prostate cancers. Looking ahead, the pharmaceutical giant intends to broaden its investigative scope by initiating studies in earlier stages of these diseases to determine if the drug can offer more durable outcomes for a wider patient population.
Comments (0)
No comments yet. Be the first!